Lancet:阿奇霉素对持续哮喘患者哮喘发作及生活质量的影响

2017-07-05 zhangfan MedSci原创

持续症状哮喘成人患者口服阿奇霉素治疗48周后哮喘发作减轻,生活质量改善。阿奇霉素有望用于持续性哮喘的治疗

哮喘恶化导致了沉重的持续性疾病负担。近日研究人员评估了口服阿奇霉素作为高剂量吸入糖皮质激素和长效支气管扩张剂的添加治疗,对于不受控制的持续性哮喘患者的疗效。 研究人员开展一项随机、双盲、安慰剂对照,平行组试验,招募的患者为成年的持续哮喘患者,患者正接受吸入糖皮质激素和长效支气管扩张剂治疗,无听力障碍或QT间期异常延长。患者随机接受阿奇霉素500mg或安慰剂,每周3次持续48周。主要终点是48周的哮喘发作率以及患者生活质量。 研究招募420名患者,其中阿奇霉素组213人,安慰剂组207人,相比于安慰剂,阿奇霉素可减少哮喘急性发作(阿奇霉素vs安慰剂;1.07每患者年[95% CI 0.85–1.29]vs1.86每患者年 [1.54–2.18]; 发病率0.59 [95% CI 0.47–0.74]; p<0.0001)。使用阿奇霉素后经历至少一次哮喘恶化的患者的比例减少(安慰剂组127例 [61%] vs 阿奇霉素组94例 [44%] p<0.0001)。阿奇霉素显著改善哮喘患者的生活质量 (调整后的平均差异:0.36 [95% CI 0.21–0.52]; p=0.001

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1250362, encodeId=0417125036270, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Sat Sep 17 23:31:01 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829057, encodeId=03cb182905e62, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Sep 27 02:37:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219094, encodeId=234021909494, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Jul 06 08:23:01 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219068, encodeId=0c36219068b9, content=很好 学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:55:08 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2022-09-17 13a65af0m37暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1250362, encodeId=0417125036270, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Sat Sep 17 23:31:01 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829057, encodeId=03cb182905e62, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Sep 27 02:37:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219094, encodeId=234021909494, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Jul 06 08:23:01 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219068, encodeId=0c36219068b9, content=很好 学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:55:08 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-09-27 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1250362, encodeId=0417125036270, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Sat Sep 17 23:31:01 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829057, encodeId=03cb182905e62, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Sep 27 02:37:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219094, encodeId=234021909494, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Jul 06 08:23:01 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219068, encodeId=0c36219068b9, content=很好 学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:55:08 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 李东泽

    这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1250362, encodeId=0417125036270, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8074025072, createdName=13a65af0m37暂无昵称, createdTime=Sat Sep 17 23:31:01 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829057, encodeId=03cb182905e62, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Sep 27 02:37:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219094, encodeId=234021909494, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Jul 06 08:23:01 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=219068, encodeId=0c36219068b9, content=很好 学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0iaeHUsbIzwsociaXY4eY8DryoMrt2gEdB9WBJl32NBRdY2JLRtDPibf3KoIM53fldicMJYbSUWVaXU/0, createdBy=e6fc75818, createdName=maymoon1983, createdTime=Thu Jul 06 07:55:08 CST 2017, time=2017-07-06, status=1, ipAttribution=)]
    2017-07-06 maymoon1983

    很好 学习啦

    0

相关资讯

J Allergy Clin Immunol Pract:哮喘和枯草热对怀孕的影响

之前的研究表明,哮喘和不良妊娠结果有关。同时,在世界范围内,哮喘和枯草热的患者数目持续增长。最近,有研究人员探究了哮喘和/或者枯草热对怀孕结果是否有不良影响。数据来源于1995年的家庭成长国家调查,包括了美国人群中,具有代表性的10847名女性的诊断哮喘、枯草热和怀孕不良结果的历史资料,年龄在15岁到44岁之间,研究人员对这些数据进行了分析。研究发现,患有过敏性表型的哮喘和枯草热的女性在不良妊娠结

JACC: Heart Failure:哮喘患者更易罹患心血管疾病

一项最新研究首次发现了哮喘病史与左心室肥厚发生率增加有关,而后者是心力衰竭的一个危险因素。

JACC-Heart Failure:哮喘可能与心衰有关

既往研究已经发现,哮喘与心脏病和脑卒中风险增加都有关。近期,一项发表在JACC心衰子刊上的研究发现,哮喘可能增加左心室肥厚风险,而后者是心衰的危险因素之一。

JACC:Heart Failure:哮喘患者更易罹患心血管疾病

一项最新研究首次发现了哮喘病史与左心室肥厚发生率增加有关,而后者是心力衰竭的一个危险因素。

Pediatr Pulmonol:支气管肺发育不良和哮喘儿童在激发试验、气道炎症和肺功能之间有何异同?

目前还没有建立对前早产儿支气管肺发育不良(BPD)的长期呼吸特征的研究。本研究的目的是描述与学龄儿童特应性哮喘相比,BPD的特征。研究结果发表在最新一期医学儿科知名期刊Pediatr Pulmonol上。

Clin Exp Allergy:成年哮喘患者合并症分析!

由此可见,在成年哮喘患者中身体和心理健康合并症是正常的。适当的识别和治疗应成为常规哮喘护理的一部分。